Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 6/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8523310 | 0.94 | CACNA1F (0.39) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D | |
| SCHEMBL6784838 | 0.93 | ADRA1A (0.39) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D | |
| SCHEMBL6715281 | 0.92 | BCL9 (0.35) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D | |
| SCHEMBL6715274 | 0.92 | BCL9 (0.35) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D | |
| SCHEMBL6216267 | 0.89 | PDE1C (0.38) | CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6194063 | 0.89 | CACNA1F (0.41) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D | |
| SCHEMBL6196841 | 0.85 | MEN1 (0.35) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D | |
| SCHEMBL7978679 | 0.83 | PDE1C (0.39) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D | |
| SCHEMBL7529769 | 0.82 | MGLL (0.36) | CACNA1FCACNA1DCACNA1SCACNA1CMEN1 | |
| SCHEMBL6782160 | 0.82 | ADRA1A (0.36) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-12-02 | — | — | US | disclosed |
| EP-1299362-A4 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2004-11-03 | — | — | EP | disclosed |
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
| EP-1299362-A1 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002006245-A1 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | SYNAPTIC PHARMARCEUTICAL CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1D 247/4885ADRA1A 224/4885ADRA1B 306/4885 |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1D 100/4885ADRA1A 88/4885ADRA1B 143/4885 |
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1D 149/4885ADRA1A 161/4885ADRA1B 156/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1D 247/4885ADRA1A 224/4885ADRA1B 306/4885 |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1D 149/4885ADRA1A 161/4885ADRA1B 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.